Emergent Biosolutions Price to Book Ratio 2010-2022 | EBS
Historical price to book ratio values for Emergent Biosolutions (EBS) over the last 10 years. The current price to book ratio for Emergent Biosolutions as of March 24, 2023 is 0.29.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Emergent Biosolutions Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2023-03-24 |
8.10 |
|
0.29 |
| 2022-12-31 |
11.81 |
$27.60 |
0.43 |
| 2022-09-30 |
20.99 |
$29.04 |
0.72 |
| 2022-06-30 |
31.04 |
$30.32 |
1.02 |
| 2021-12-31 |
43.47 |
$31.56 |
1.38 |
| 2021-09-30 |
50.07 |
$28.36 |
1.77 |
| 2021-06-30 |
62.99 |
$28.75 |
2.19 |
| 2021-03-31 |
92.91 |
$28.41 |
3.27 |
| 2020-12-31 |
89.60 |
$27.25 |
3.29 |
| 2022-03-31 |
41.06 |
$31.26 |
1.31 |
| 2020-09-30 |
103.33 |
$23.61 |
4.38 |
| 2020-06-30 |
79.08 |
$22.66 |
3.49 |
| 2020-03-31 |
57.86 |
$20.55 |
2.82 |
| 2019-12-31 |
53.95 |
$21.05 |
2.56 |
| 2019-09-30 |
52.28 |
$20.06 |
2.61 |
| 2019-06-30 |
48.31 |
$19.16 |
2.52 |
| 2019-03-31 |
50.52 |
$19.21 |
2.63 |
| 2018-12-31 |
59.28 |
$19.74 |
3.00 |
| 2018-09-30 |
65.83 |
$19.26 |
3.42 |
| 2018-06-30 |
50.49 |
$18.76 |
2.69 |
| 2018-03-31 |
52.65 |
$17.69 |
2.98 |
| 2017-12-31 |
46.47 |
$18.47 |
2.52 |
| 2017-09-30 |
40.45 |
$16.04 |
2.52 |
| 2017-06-30 |
33.91 |
$15.10 |
2.25 |
| 2017-03-31 |
29.04 |
$14.90 |
1.95 |
| 2016-12-31 |
32.84 |
$14.69 |
2.23 |
| 2016-09-30 |
31.53 |
$13.53 |
2.33 |
| 2016-06-30 |
26.35 |
$16.64 |
1.58 |
| 2016-03-31 |
34.06 |
$16.74 |
2.03 |
| 2015-12-31 |
37.49 |
$16.75 |
2.24 |
| 2015-09-30 |
26.70 |
$15.57 |
1.71 |
| 2015-06-30 |
30.88 |
$14.51 |
2.13 |
| 2015-03-31 |
26.95 |
$14.03 |
1.92 |
| 2014-12-31 |
25.52 |
$14.67 |
1.74 |
| 2014-09-30 |
19.97 |
$13.67 |
1.46 |
| 2014-06-30 |
21.05 |
$13.02 |
1.62 |
| 2014-03-31 |
23.68 |
$12.80 |
1.85 |
| 2013-12-31 |
21.54 |
$13.36 |
1.61 |
| 2013-09-30 |
17.85 |
$12.86 |
1.39 |
| 2013-06-30 |
13.51 |
$12.41 |
1.09 |
| 2013-03-31 |
13.10 |
$12.07 |
1.09 |
| 2012-12-31 |
15.03 |
$12.33 |
1.22 |
| 2012-09-30 |
13.32 |
$11.85 |
1.12 |
| 2012-06-30 |
14.20 |
$11.67 |
1.22 |
| 2012-03-31 |
14.99 |
$11.40 |
1.32 |
| 2011-12-31 |
15.78 |
$11.57 |
1.36 |
| 2011-09-30 |
14.46 |
$10.72 |
1.35 |
| 2011-06-30 |
21.13 |
$10.63 |
1.99 |
| 2011-03-31 |
22.64 |
$10.13 |
2.23 |
| 2010-12-31 |
21.98 |
$10.67 |
2.06 |
| 2010-09-30 |
16.17 |
$8.90 |
1.82 |
| 2010-06-30 |
15.31 |
$8.40 |
1.82 |
| 2010-03-31 |
15.73 |
$8.04 |
1.96 |
| 2009-12-31 |
12.73 |
$7.91 |
1.61 |
| 2009-09-30 |
16.55 |
$7.71 |
2.15 |
| 2009-06-30 |
13.43 |
$7.60 |
1.77 |
| 2009-03-31 |
12.66 |
$7.04 |
1.80 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.406B |
$1.121B |
|
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
|
